204 related articles for article (PubMed ID: 15657294)
1. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.
Lurquin C; Lethé B; De Plaen E; Corbière V; Théate I; van Baren N; Coulie PG; Boon T
J Exp Med; 2005 Jan; 201(2):249-57. PubMed ID: 15657294
[TBL] [Abstract][Full Text] [Related]
2. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
[TBL] [Abstract][Full Text] [Related]
3. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
4. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Lonchay C; van der Bruggen P; Connerotte T; Hanagiri T; Coulie P; Colau D; Lucas S; Van Pel A; Thielemans K; van Baren N; Boon T
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
[TBL] [Abstract][Full Text] [Related]
5. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
8. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
9. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
Zhang Y; Sun Z; Nicolay H; Meyer RG; Renkvist N; Stroobant V; Corthals J; Carrasco J; Eggermont AM; Marchand M; Thielemans K; Wölfel T; Boon T; van der Bruggen P
J Immunol; 2005 Feb; 174(4):2404-11. PubMed ID: 15699177
[TBL] [Abstract][Full Text] [Related]
11. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
13. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
14. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
16. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.
Ma W; Vigneron N; Chapiro J; Stroobant V; Germeau C; Boon T; Coulie PG; Van den Eynde BJ
Int J Cancer; 2011 Nov; 129(10):2427-34. PubMed ID: 21207413
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
Karanikas V; Lurquin C; Colau D; van Baren N; De Smet C; Lethé B; Connerotte T; Corbière V; Demoitié MA; Liénard D; Dréno B; Velu T; Boon T; Coulie PG
J Immunol; 2003 Nov; 171(9):4898-904. PubMed ID: 14568971
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
